NCT06141590已完成1 期
A Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- AUCt
研究概览
简要总结
This study was open-label, randomized, fed, single-dose, 2-groups, 2 periods, crossover designe to compare the safety and pharmacokinetics of UI068 and co-administration of UIC202205 and UIC202206.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects over the ages of 19 at screening
- •Subjects whose body weight over 60 kg and having a body mass index (BMI) of over than 18.0 and less than 30.0 kg/m2 at screening (☞ BMI(kg/m2) = Weight(kg)/{Height(m)}2)
- •There are no clinically significant congenital diseases/chronic diseases/ pathological symptoms or finding at the screening
- •he principal investigator determines to be suitable test subjects as a result of diagnostic tests and electrocardiogram tests etc.
- •From the date of first to the last administration of the investigational drug Until 7 weeks , tester or spouse or partner must use a method of contraception recognized in clinical trials.
- •The tester who is signed after being explained and understanding about purpose and content of this clinical trial, characteristics of the investigational drug.
排除标准
- •Clinically significant diseases related to the digestive system, cardiovascular system, endocrine system, respiratory system, blood/tumor, infectious disease, kidney and genitourinary system, mental/nervous system, musculoskeletal system, immune system, ENT system, skin system, and ophthalmic system. Those who have or have a history of
- •Those with a history of gastrointestinal surgery (excluding simple appendectomy or hernia surgery) that may affect drug absorption or gastrointestinal disease
- •Those who took drugs that induce or inhibit drug-metabolizing enzymes, such as barbiturates, within 1 month of the first dose, or took drugs that may interfere with this clinical trial within 10 days of the first dose.
- •A person who participated in another clinical trial or bioequivalence test and administered an investigational drug within 6 months of the first administration date
- •Those who donated whole blood or component blood within 2 weeks or received a blood transfusion within 4 weeks of the first administration date
- •Those who meet the following conditions within 1 month of the first medication date
- •Alcohol consumption exceeding 21 drinks/week on average for men
- •For women, alcohol consumption exceeds an average of 14 drinks/week
- •(1 glass = 50 mL of soju or 30 mL of liquor or 250 mL of beer)
- •Smoking more than 20 cigarettes per day on average
- •Those who fall under the following
- •Patients with hypersensitivity to clinical investigational drugs or ingredients contained in clinical investigational drugs
- •Persons with a history of hypersensitivity to biguanide drugs
- •Patients with the following diseases
- •Patients with moderate (stage3b) and severe renal impairment (eGFR<45mL/min/1.73m2), Acute conditions that can affect kidney function, such as diabetes, serious infections, cardiovascular collapse (shock), acute myocardial infarction, and sepsis
- •Patients with acute and unstable heart failure
- •Patients undergoing tests requiring intravenous administration of radioiodine contrast material (e.g., intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast agent, etc.)
- •Patients with acute or chronic metabolic acidosis, including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis
- •Diabetic precoma
- •Patients with severe infections or severe traumatic systemic disorders
- •Patients with malnutrition, starvation, weakness, pituitary dysfunction or adrenal dysfunction
- •Patients with acute or chronic diseases that can cause tissue hypoxia such as liver dysfunction, respiratory failure, acute myocardial infarction, and shock, excessive alcohol intake, and gastrointestinal disorders such as dehydration, diarrhea, and vomiting
- •Persons judged by the principal investigator to be unsuitable for participation in this clinical trial for reasons other than the above selection/exclusion criteria
- •For female volunteers, those who are pregnant, suspected of being pregnant, or lactating
研究组 & 干预措施
UI068
Experimental
干预措施: administration of UI068 (Drug)
UIC202205, UIC202206
Experimental
干预措施: administration of UIC202205, UIC202206 (Drug)
结局指标
主要结局
AUCt
时间窗: 0 to 72hr
Evaluation PK for Linagliptin and Metformin after single dose
Cmax
时间窗: 0 to 72hr
Evaluation PK for Linagliptin and Metformin after single dose
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male SubjectsHealthy VolunteersNCT02088918IlDong Pharmaceutical Co Ltd40
已完成
1 期
Clinical Trial to Assess the Safety and Pharmacokinetics of HUG116 Tablet and Viread® Tablet in Healthy Male VolunteersHealthyNCT02902523Huons Co., Ltd.50
Unknown
1 期
Intranasal Human FGF-1 for Subjects With Parkinson's DiseaseParkinson DiseaseNCT05493462Zhittya Genesis Medicine, Inc.4
尚未招募
2 期
Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal CancerAdvanced Colorectal CancerNCT05364489The First Affiliated Hospital of Zhengzhou University20
已完成
1 期
A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)TuberculosisNCT04239313Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.30